Brief: Oncolytics Biotech Receives Final Advice Letter From European Medicines Agency For Reolysin In Metastatic Breast Cancer
Dec 5 (Reuters) - Oncolytics Biotech Inc ONC.TO :
* ONCOLYTICS BIOTECH RECEIVES FAVORABLE FINAL ADVICE LETTER
FROM
THE EUROPEAN MEDICINES AGENCY FOR REOLYSIN IN METASTATIC BREAST
CANCER
* ONCOLYTICS BIOTECH INC - PROPOSED PHASE 3 STUDY DESIGN IS
FOUND
ACCEPTABLE AND CAN FORM BASIS OF A MARKETING AUTHORIZATION
APPLICATION
* ONCOLYTICS BIOTECH INC - EMA ADVICE CONSISTENT WITH
FEEDBACK
RECEIVED FROM FDA PAVING WAY FOR A GLOBAL PHASE 3 STUDY
Source text for Eikon: ID:nCNWP541ba
Further company coverage: ONC.TO
((Bangalore.newsroom@thomsonreuters.com;))
Recent news on Oncolytics Biotech
See all newsBrief: Oncolytics Biotech Announces Clinical Supply Agreement To Evaluate Pelareorep In Combination With Loqtorzi In Squamous Cell Anal Carcinoma
Brief: Oncolytics Says Pelareorep Shows Durable Survival Benefit in Anal Cancer
Brief: Oncolytics Biotech Expects Final Cohort 4 Results Of Goblet Study In Q4 2026
Brief: Oncolytics Biotech® Secures Patent Protection To Late 2040S And Provides Intellectual Property Portfolio Update
Brief: Oncolytics Biotech® Aligns With FDA On Registrational Path For Second-Line Ras-Mutant Mss Colorectal Cancer